Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Helena Adamis"'
Autor:
Edwin Kingsley, Sebastian Grosicki, Michal Kwiatek, Antonio Salar, Sylvia Snauwaert, Ying Wang, Helena Adamis, Luqiang Wang, Julien Depaus
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S163
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82aa0438c985a3d731e61481f7e64fbb
https://doi.org/10.1016/s2152-2650(22)01001-1
https://doi.org/10.1016/s2152-2650(22)01001-1
Autor:
Mehdi Hamadani, Yuliya Linhares, Mitul Gandhi, Michael Chung, Helena Adamis, David Ungar, Carmelo Carlo-Stella, Ed Kingsley, Julien Depaus, Sylvia Snauwaert, Michal Kwiatek, Javier López-Jiménez
Publikováno v:
Journal of Clinical Oncology. 40:TPS7591-TPS7591
TPS7591 Background: Patients (pts) with refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes with standard treatment. Loncastuximab tesirine (loncastuximab tesirine-lpyl; Lonca), an antibody-drug conjugate (ADC) compr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd64a9af59b824eb5ab8196080b5be47
https://doi.org/10.1200/jco.2022.40.16_suppl.tps7591
https://doi.org/10.1200/jco.2022.40.16_suppl.tps7591
Autor:
Carmelo Carlo-Stella, Michael Chung, Helena Adamis, Mitul Gandhi, Yuliya Linhares, David Ungar, Mehdi Hamadani
Publikováno v:
Journal of Clinical Oncology. 39:TPS7574-TPS7574
TPS7574 Background: Patients (pts) with DLBCL for whom frontline therapy is unsuccessful and who are ineligible for autologous stem cell transplantation have poor outcomes with salvage therapy. Single-agent loncastuximab tesirine (Lonca), an antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48cdaf1be63711411a97e0513611c22d
https://doi.org/10.1200/jco.2021.39.15_suppl.tps7574
https://doi.org/10.1200/jco.2021.39.15_suppl.tps7574
Autor:
Maher Azer, Daniel W. Coyne, Mario Fraticelli, Steven J. Rosansky, Giuseppe Villa, Ulrich Beyer, Sanjay Dalal, Helena Adamis, Charmaine E. Lok, Bruce Spinowitz
Publikováno v:
American Journal of Nephrology. 28:280-289
Background/Aims: This Phase III study examined the efficacy and safety of C.E.R.A., a continuous erythropoietin receptor activator, given once every 2 weeks (Q2W) via subcutaneous or intravenous injection using pre-filled syringes, for maintaining he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65a819fced38b94520091e00a5eb3bb1
https://doi.org/10.1159/000111115
https://doi.org/10.1159/000111115
Autor:
Benno Jungblut, Kaj Grandien, Carola B. Sigrist, Ralf J. Sommer, Isabel Schlak, Andreas Eizinger, Helena Adamis
Publikováno v:
Invertebrate Reproduction & Development. 36:57-65
Summary Over the last few years vulva development in nematodes has been used as a model system to study the evolution of developmental processes by carrying out cell lineage and cell ablation studies in various nematodes. Furthermore, a genetic and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7257c189ee03cf441df21c895869a17a
https://doi.org/10.1080/07924259.1999.9652678
https://doi.org/10.1080/07924259.1999.9652678
Autor:
Eugen Tausch, Christoph Renner, Stephan Stilgenbauer, Eva Mikuskova, Osman Ilhan, Darius Woszczyk, Nicola Tyson, Tom Moore, Francesc Bosch, Robin Foà, Helena Adamis, Véronique Leblonde, Sebastian Böttcher
Publikováno v:
Blood. 126:493-493
Background The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101; GAZYVA/GAZYVARO; G) combined with chlorambucil (Clb) has superior efficacy to Clb monotherapy and to rituximab plus Clb with an acceptable safety profile in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::270f92d2929b2ae317cd28f2a6089b0f
https://doi.org/10.1182/blood.v126.23.493.493
https://doi.org/10.1182/blood.v126.23.493.493